Dme Capital Management, LP Gain Therapeutics, Inc. Transaction History
Dme Capital Management, LP
- $2.33 Trillion
- Q2 2025
A detailed history of Dme Capital Management, LP transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Dme Capital Management, LP holds 566,130 shares of GANX stock, worth $866,178. This represents 0.04% of its overall portfolio holdings.
Number of Shares
566,130
Previous 566,130
-0.0%
Holding current value
$866,178
Previous $1.08 Billion
5.76%
% of portfolio
0.04%
Previous 0.05%
Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
39Shares Held
4.47MCall Options Held
37.9KPut Options Held
0-
Jones Financial Companies Lllp677KShares$1.04 Million0.0% of portfolio
-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$900,2670.1% of portfolio
-
Vanguard Group Inc Valley Forge, PA534KShares$817,5580.0% of portfolio
-
Geode Capital Management, LLC Boston, MA290KShares$444,4060.0% of portfolio
-
Marshall Wace, LLP London, X0276KShares$422,9420.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $18.2M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...